In this episode of Talk With Turek, Dr. Paul Turek and co-host Rob Clyde welcome special guest Dr. John K. Amory, MD, MPH, Professor at the University of Washington, to discuss a breakthrough that is proving to be a true game changer in the field of reproductive health.

What you’ll learn in this episode:

• How isotretinoin (best known as Accutane®) has been shown to stimulate sperm production in severely infertile men.

• Why retinoic acid is critical for spermatogenesis and healthy sperm production

• Results from a brand-new peer-reviewed study: in a group of 30 men with azoospermia or cryptozoospermia, 37% produced motile ejaculated sperm after 3–6 months of isotretinoin therapy Real-world outcomes: embryos created, pregnancies achieved, and babies born

• Why this treatment, although off-label, offers real hope to men once told “there’s no chance.” This medication must be artfully monitored and requires specialized oversight and management by an experienced reproductive urology practice.

• How collaboration between specialists is breaking down stigma and driving innovation in male fertility

At The Turek Clinic, our mission is to put patients first. That means understanding every unique situation, exploring every option, and guiding patients toward the best path forward — whether that involves surgery, advanced diagnostics, or groundbreaking new therapies.

Tune in to Episode 10 of Talk With Turek on your favorite podcast platform, or watch here, to learn how this discovery could transform the future of infertility treatments.

*Isotretinoin is not FDA-approved for male infertility; this is off-label use.

**Accutane® is a registered trademark of Hoffmann-La Roche Inc.; use herein is for identification only.